Skip to main content
Move the World.
Uganda Begins Massive New Ebola Vaccine Study

The Ebola outbreak in the northeastern provinces of the Democratic Republic of the Congo continues to rage. It is now the second deadliest outbreak on record, behind only the West African outbreak in 2014. The epicenter is in North Kivu, a conflict-torn province which shares borders with Rwanda and Uganda.

In June, a small number of Ugandan Ebola cases were the first to cross borders from the current Congo outbreak. The country will now play host a massive trial study of a new Ebola vaccine.

A New Weapon in the War on Ebola

A vaccine made by American pharmaceutical company Merck is already being used in Congo, with promising results. The vaccine is being used in outbreak control, in a method known as “ring vaccination.”

Ring vaccination works by encircling and cutting of the virus’s path of transmission; think firefighters clearing brush ahead of a wildfire to rob it of fuel. When a confirmed case of Ebola is found, epidemiologists trace whoever came into contact with that person.The people who contacted the Ebola patient (and then those who contacted them) are vaccinated in expanding rings until the virus is stopped in its tracks.

As confirmed cases continue to swell and the situation risks spiraling even further out of control, the World Health Organization (WHO) has made Merck’s vaccine available to ever broader circles. This comes with a catch, however: there is a finite supply of the Merck vaccine, and making more takes money and time. Congolese officials are also opposed to field testing another vaccine, concerned that it would complicate the outbreak response.

Enter Uganda

The Uganda trial will be testing a two-step vaccine — known as a “prime-boost” vaccine — made by Janssen Vaccines and Prevention. The first dose “primes” the immune system with antigen DNA; the second one, given 56 days later, “boosts” it with more antigen protein. Because it uses multiple methods to stimulate production of antibodies, it is thought to be more effective than traditional vaccination strategies.

According to the London School of Hygiene and Tropical Medicine (LSHTM), which is sponsoring the study, scientists will attempt to vaccinate 800 health workers and frontline responders — burial teams, ambulance drivers, cleaners — who are most at risk of becoming infected. These subjects will be studied for two years to determine how well the vaccine protects against Ebola and how long that protection lasts. 

If the vaccine proves not only effective but long-lasting, it could take the pressure off using only one source of vaccine and be more effective in closing the rings.

Information will also be gathered about the attitudes and perceptions towards the vaccines. This social study will be crucial for saving lives.

The Cold Water

Vaccines and antivirals are already working well in the DRC, but outbreak response has been whipsawed by the various armed groups active in the region and the mistrust and anger some have directed at healthcare workers.

North Kivu has long been unstable, host to an alphabet soup of bad actors that have in turn fostered the growth of powerful local protection militias, known by the catch-all name Mai-Mai. Such is the power of the Mai-Mai that even Congolese national forces do not enter their territory.

When Ebola is traced to a place of Mai-Mai control, responders must be able to negotiate with their generals. Doing so correctly not only makes the response safer but more effective; the general has the power to ensure his whole village follows safe Ebola protocols and gets vaccinated.

 But years of corruption and violence makes trusting the responders, who take away their loved ones, deny families the funeral rites their deceased require, and appear ghoulish in their masked protective equipment, difficult. Ebola treatment centers have been attacked and burned, and healthcare workers are sometimes kidnapped and even killed.

Getting the vaccine to the people who need it in these conditions remains the greatest challenge; even if the Ugandan vaccine proves highly effective, that means little if it cannot be used. Ultimately, the data gathered in Uganda about perceptions and attitudes towards the vaccines may prove to be the most important part of the study.

Ed. note: This piece has been updated from an earlier draft.

Stay up to date

Up Next

Biohacking
Biohacker’s Prosthetic Arm Lets Him Play a Synthesizer With His Mind
Biohacker’s Prosthetic Arm Lets Him Play a Synthesizer With His Mind
Biohacking
Biohacker’s Prosthetic Arm Lets Him Play a Synthesizer With His Mind
Biohacker Bertolt Meyer has built the SynLimb, a controller that attaches to his prosthetic arm, allowing him to control his modular synthesizer with his mind.

Biohacker Bertolt Meyer has built the SynLimb, a controller that attaches to his prosthetic arm, allowing him to control his modular synthesizer with his mind.

Dispatches
"Q" Probably Won't Make You Rich, but It's an Experiment Worth Watching
Dispatches
"Q" Probably Won't Make You Rich, but It's an Experiment Worth Watching
It's not the next Bitcoin (or a path to riches), but it's an intriguing idea.
By Brendan Markey-Towler

It's not the next Bitcoin (or a path to riches), but it's an intriguing idea.

Intel
The Future of Cancer Research
The Future of Cancer Research
Watch Now
Intel
The Future of Cancer Research
Intel's Bryce Olson used genomic sequencing to help fight his cancer. Now he’s helping researchers use artificial intelligence to discover entirely new cancer treatments.
Watch Now

Intel employee Bryce Olson was diagnosed with stage 4 prostate cancer. When the standard of care didn’t work, Bryce turned to genomic sequencing which allowed his doctors to identify specific genetic drivers of his disease and specific treatments and clinical trials that were a fit for his cancer. This precision medicine approach helped send his cancer into remission for several years. Now that his cancer has returned,...

Dispatches
Scientists Physically "Transplant" a Memory in Snails
Scientists Physically
Dispatches
Scientists Physically "Transplant" a Memory in Snails
The experiment breaks the conventional wisdom about what memories are made of.

The experiment breaks the conventional wisdom about what memories are made of.

Using Fashion to Fool Facial Recognition
Using Fashion to Fool Facial Recognition
Watch Now
Using Fashion to Fool Facial Recognition
Facial recognition software is everywhere - and being used for surveillance. One fashion designer is coming up with looks that fool the software.
Watch Now

With the use of facial recognition technology on the rise, privacy advocates are increasingly concerned about the potential for misuse. Artist Adam Harvey is working to show how fashion can be used to fool facial recognition technology. His most recent project, CV Dazzle, is a scarf with fabric that looks like camouflage but contains elements that mimic a human face. These elements can successfully confuse the software...

Coded
The Unhackable Email Service
The Unhackable Email Service
Watch Now
Coded
The Unhackable Email Service
Edward Snowden’s email service of choice wants to make mass surveillance obsolete.
Watch Now

Ladar Levison’s email service counted Edward Snowden among its users. But, when the FBI demanded Levison hand over Snowden’s communications, Levison destroyed the company’s servers. Now, he’s back with a more secure version of the service that could make mass surveillance obsolete.

The New Space Race
Who Owns the Moon?
Who Owns the Moon?
The New Space Race
Who Owns the Moon?
Throughout history, different organizations, governments, and even individuals have attempted to establish rules...
By Mike Riggs

Throughout history, different organizations, governments, and even individuals have attempted to establish rules for, and ownership of, outer space.

Self-Driving Cars are Finally Here. Sort Of.
Self-Driving Cars are Finally Here. Sort Of.
Self-Driving Cars are Finally Here. Sort Of.
Uber rolled out self-driving cars in Pittsburgh, but they're not totally autonomous. Yet. Under Pennsylvania law,...
By Mike Riggs

Uber rolled out self-driving cars in Pittsburgh, but they're not totally autonomous. Yet. Under Pennsylvania law, every car still needs an operator.